Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethiopia malaria in-vivo antimalarial effectiveness study 2021-22
PACTR202110520435408Phase 4Recruiting
- Sponsor
- Columbia University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artesunate + pyronaridine, primaquine, chloroquine and artemether + lumefantrine in malaria and Malaria (6 arms), sponsored by Columbia University. Primary endpoint: In-vivo antimalarial effectiveness. Started Oct 2021; status: recruiting.
02
Drugs
artesunate + pyronaridineprimaquinechloroquineartemether + lumefantrine
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on PACTR202110520435408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202110520435408.